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Efficacy of transoral fundoplication for treatment
of chronic gastroesophageal reflux disease
incompletely controlled with high-dose
proton-pump inhibitors therapy: a randomized,
multicenter, open label, crossover study
Karim Sami Trad1,2*, Gilbert Simoni3, William Edris Barnes4, Ahmad Bassel Shughoury5,6, Mamoon Raza7,8,
Jeffrey Alan Heise9, Daniel Gilles Turgeon1,2, Mark Alan Fox10,11 and Peter George Mavrelis5,6

Abstract
Background: The aim of this randomized, crossover study was to determine if transoral fundoplication (TF) could
further improve clinical outcomes in partial responders to high-dose (HD) proton-pump inhibitor (PPI) therapy and
to evaluate durability of TF.
Methods: In seven United States centers, patients with hiatal hernia ≤2 cm and abnormal esophageal acid exposure
(EAE) were randomized to TF (n = 40) or HD PPIs (n = 23) group. At 6-month follow-up, PPI patients underwent
crossover. We assessed clinical outcomes 6-month post TF in crossover patients (COP), as compared to 6-month
of HD PPI therapy, and 12-month outcomes in patients initially randomized to TF. The primary outcome was
symptom control evaluated by Reflux Disease Questionnaire and Reflux Symptom Index. Secondary outcomes
included healing of esophagitis, normalization of EAE and PPI use after TF. We analyzed 21 COP and 39 TF patients.
McNemar’s test or Fisher exact test was used to compare proportions.
Results: Of 63 randomized patients, 3 were lost to follow-up, leaving 39 TF and 21 COP for analyses. In the COP,
TF further improved control of regurgitation and of atypical symptoms achieved after six months of HD PPIs. Of
20 patients with GERD symptoms after six months of high-dose PPI therapy, 65% (13/20) reported global elimination of
troublesome regurgitation and atypical symptoms post TF off PPIs; 67% (6/9) reported no troublesome regurgitation.
Esophagitis further healed in 75% (6/8) of patients. Seventy-one percent of COP patients were off PPIs six months
following TF. Normalization of EAE decreased from 52% after HD PPIs (on PPIs) to 33% after TF (off PPIs), p =0.388. In
the original TF group, 12-month post TF, 77% of patients achieved complete symptom control, 82% ceased PPI therapy,
100% healed esophagitis and 45% normalized EAE.
Conclusions: The results of this study indicate that in patients with incomplete symptom control on high-dose PPI
therapy TF may provide further elimination of symptoms and esophagitis healing. In the original TF group, the clinical
outcomes of TF remained stable between 6- and 12-month follow-up.
Trail registration: Clinicaltrials.gov: NCT01647958.
Keywords: TIF, EsophyX, Atypical GERD symptoms, Regurgitation
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Background
Gastroesophageal reflux disease (GERD) is a chronic condition afflicting millions of Americans on a daily basis [1].
Despite major medical therapeutic advances in the past
three decades, treatment alternatives remain imperfect for
a portion of patients suffering from persistent troublesome
symptoms, as defined by the Montreal consensus statement, while on daily high-dose proton-pump inhibitors
(PPIs) therapy [2,3]. Laparoscopic fundoplication, while
currently considered the gold standard alternative to
medical therapy, has seen decreased popularity mostly
due to recurrent symptoms requiring medical therapy and
the associated troublesome side effects such as dysphagia
and gas bloat [4,5]. PPI therapy, while the most common
and effective treatment for patients with moderate to
severe heartburn, provides unsatisfactory or incomplete
responses to 20-40% of patients, mostly those suffering
from regurgitation or extra-esophageal manifestations
of GERD [6,7].
The EsophyX device (EndoGastric Solutions, Inc.,
Redmond, WA) is one of several endoluminal platforms
developed to offer a less invasive procedural alternative to
treat GERD [8]. The transoral fundoplication (TF) technique has combined symptomatic success with an acceptable safety profile and few post fundoplication side effects
[9]. While TF appears to be an attractive alternative to
current medical and surgical therapies in select patients,
there are no randomized crossover studies evaluating TF
in patients who respond incompletely to high-dose PPIs.
The TEMPO (TF EsophyX vs. Medical PPI Open Label
Trial) randomized crossover trial was designed with a dual
aim; (1) to compare the efficacy of TF to high-dose PPI in
patients with troublesome symptoms of GERD and (2) to
investigate the effectiveness of the TF procedure used as a
cross over strategy in patients who remained incompletely
treated on high-dose PPIs. Preliminary six month results
comparing two parallel treatment arms of this trial were
reported elsewhere [10]. For the present study, we hypothesized that TF would enhance the therapeutic effects
achieved by high-dose PPI therapy in the same group of
patients (crossover group), and that the clinical outcomes
of TF would remain stable over time in patients initially
randomized to the TF group.
Methods
Study design and patients

This prospective, comparative, randomized study with a
crossover group enrolled 63 patients between June and
August 2012 at seven institutions in the United States. Included were patients with daily troublesome regurgitation
and/or atypical GERD symptoms (Montreal criteria) on
PPIs, abnormal 48-hour ambulatory pH test defined as%
time pH <4 greater than 5.3% of the total recording period
[11] and a history of daily PPI use for at least six months.
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We excluded patients with a body mass index (BMI)
greater than 35 kg/m2, Los Angeles grade C or D esophagitis [12], hiatal hernia >2 cm in either dimension, Hill
grade valve III or IV [13,14] and Barrett’s esophagus >2 cm.
The study was approved by the institutional review board
of each participating institution and appropriately registered
(clinicaltrials.gov: NCT01647958) [10]. Western Institutional Review Board approved the study at the following centers: The George Washington University School
of Medicine and Health Sciences, Washington, District of
Columbia; Reston Surgical Associates, Reston, Virginia; Advanced Gastroenterology, Inc., Thousand Oaks, California;
Livingston Hospital and Healthcare Services, Inc. CAH,
Salem, Kentucky; Saint Mary Medical Center, Hobart,
Indiana; Internal Medicine Associates, Merrillville, Indiana;
Indiana Medical Research, Elkhart, Indiana; Unity Surgical Hospital, Mishawaka, Indiana; Heartburn Center/
Rehabilitation Department, Hancock Regional Hospital,
Greenfield, Indiana; Crossville Medical Group, Crossville,
Tennessee and Cumberland Medical Center, Crossville,
Tennessee. Additionally, due to the local regulatory requirements, the Reston Hospital Center Institutional Review Board approved the study at The George Washington
University School of Medicine and Health Sciences,
Washington, District of Columbia and Reston Surgical
Associates, Reston, Virginia. The participating centers
were led by gastroenterologists (3) and surgeons (4).
All patients provided written informed consent before
randomization.
In our community settings, the public at large and some
institutional review boards were reluctant to include a
sham procedure arm in our study design. Considering the
previously published results of the safety and effectiveness
of TF and taking into account the concerns about subjecting study patients to unnecessary risks associated with a
sham procedure, we employed a non-blinded study design
for this post market, phase IV randomized trial.
Pretreatment evaluation and randomization

Baseline data, while on PPIs, were collected during the initial visit using three standardized tools: (i) Reflux Disease
Questionnaire (RDQ), (ii) Reflux Symptom Index (RSI)
and (iii) Gastroesophageal Health-related Quality of Life
(GERD-HRQL). Patients who reported daily troublesome regurgitation and/or atypical symptoms on daily
PPIs underwent esophagogastroduodenoscopy (EGD)
and 48-hr pH monitoring after a ‘wash out’ period of
at least seven days. Symptom assessment was repeated
off PPIs using the same GERD questionnaires. Barium
swallow and esophageal motility were used selectively
when clinically indicated.
Randomization was done by computer-generated block
sequence with stratification according to participating centers. The size of randomization blocks was nine. Patients
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were randomly assigned to be treated either with TF or
high dose PPI targeting a 2(TF):1(PPI) ratio via sealed
opaque envelopes. Patients who met the eligibility criteria
were informed of the treatment allocation in the office by
opening the envelopes provided by an independent statistician in their presence.
Treatments

In the TF group, investigators used an EsophyX-2 device
to create a partial esophago-gastric fundoplication following the previously described TIF 2.0 protocol [15].
Briefly, the device is introduced over a flexible endoscope
and inserted into the stomach under constant endoscopic
visualization. The device and endoscope are retroflexed.
The helical retractor is engaged into the tissue just below
the Z line. The fundus of the stomach is then folded up
and wrapped around the distal esophagus utilizing the
tissue mold, the chassis and the helix as an anchor.
After locking all the tissue manipulating elements, the
invaginator is activated to allow the separation of the
gastroesophageal junction from the diaphragm. The polypropylene “H” fasteners are then delivered through the tissue. The maneuver is repeated at three additional positions
to create a full thickness, partial gastro-esophageal fundoplication. An additional movie file shows the TF procedure
in more details [see Additional file 1]. An intraoperative
endoscopy under general anesthesia is performed immediately before introducing the device to confirm Hill grade
and size of hiatal hernia.
After TF, patients were kept overnight for observation.
Patients were instructed to stop PPI therapy two weeks
after TF, to follow the standard post-fundoplication diet
and to refrain from vigorous physical activities for the
first 6 weeks.
In the PPI group, patients were instructed to take highdose PPI therapy splitting the dose into twice daily before
breakfast and dinner. For the purpose of this study, we defined high-dose PPI therapy as the maximal allowed dose
set by the manufacturers, as spelled out in the labeled
indications.
Follow-up and crossover

At 6-month follow-up, all patients completed symptom
assessment using the same GERD specific questionnaires.
Patients in the TF group underwent EGD and 48-hr pH
metry off PPIs for at least 7 days. Patients in the PPI group
underwent objective testing on high-dose PPI therapy.
After completing 6-month visit, patients from the original
PPI group underwent TF (crossover group). Patients from
the original TF group underwent the same assessments
at 12-month follow-up visit. We are reporting on the
potential additional therapeutic effects of TF in a crossover population who had achieved a partial response to
dose escalation of PPI therapy. Additionally, we are
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reporting the clinical outcomes at 12-month follow-up
in patients initially randomized to the TF group.
Outcomes

The primary endpoint was elimination of daily troublesome regurgitation or atypical symptoms. Clinical success
was defined by the elimination of troublesome regurgitation per Montreal consensus definition [3], as evaluated by
the RDQ questionnaire. The elimination of daily troublesome atypical symptoms was assessed by the RSI questionnaire (each individual atypical score ≤2) score. Secondary
endpoints included PPI use, healing of reflux esophagitis
and normalization of esophageal acid exposure (EAE).
Heartburn, dysphagia and bloating were assessed using
GERD-HRQL; excess flatulence was assessed with a standalone question. We also performed correlation analyses
to measure the degree of association between subjective
and objective (pH) outcomes. Finally, we performed univariate and multivariate logistic regression analyses to detect preoperative factors associated with normalization of
EAE.
Statistical methods

Statistical analysis was performed using JMP 10.0 (SAS,
Cary, North Carolina) statistical program. With a sample
size of 28 (TF) and 14 (PPIs) patients, a two group Fisher
exact test would have a power of 80% to demonstrate a significant difference between groups. Under the assumption
that more than 70% of the patients allocated to the TF
group would have their daily troublesome symptoms eliminated compared to ≤20% in the PPI group, and a twosided α error of 0.05, the predetermined sample size would
provide an 80% power to detect a significant difference
between the two groups. Results are presented as means
(standard deviation) or percent (counts). Comparison of
means was done with analysis of variance with post-hoc
Tukey’s Honesty Significant Difference test. As appropriate,
McNemar’s test or Fisher exact test was used to compare
proportions. Relationship between post-treatments pH outcomes and patient reported subjective outcomes were estimated using Spearman’s rank correlation (rho). Univariate
and stepwise backward multivariate logistic regression analyses were performed to examine associations between preoperative pH parameters and normalization of EAE. A p
value of less than 0.05 was considered significant. All
authors had access to the study data and reviewed and
approved the manuscript.

Results
Among 196 chronic GERD patients referred to our institutions for an antireflux procedure, 32% (63/196) were
randomized (Figure 1). Baseline characteristics of enrolled
patients were balanced between the TF and PPI group, including proportion of patients who were on high-dose PPI
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Figure 1 CONSORT diagram of the study.

therapy at screening; 31% of TF patients versus 24% of PPI
patients (Table 1). There were no reports of serious adverse events associated with the TF procedure in either
group. The procedure data are presented in Table 2.

Crossover patients (6-month follow-up)
Primary endpoint

Six months after TF, 65% [13/20, 95% confidence interval
(CI), 43 to 82] of patients reported global elimination of
troublesome regurgitation and any atypical symptoms off
PPI therapy. One patient who reported global elimination
of GERD symptoms after high-dose PPI therapy was excluded from this analysis. Of 9 patients who reported
troublesome regurgitation after being on high-dose PPI
therapy for six months, 67% (6/9, 95% CI, 35 to 88) reported no troublesome regurgitation six months following
TF while off PPIs. TF, as compared to high-dose PPIs, further improved quality of life scores and control of various
atypical symptoms such as hoarseness, throat cleaning,

postnasal drip and troublesome or annoying cough
(Table 3).
Secondary endpoints

PPI use, healing of reflux esophagitis and pH normalization
in the crossover group are shown in Figure 2. Of six patients who were back on PPI therapy after TF, 67% (4/6,
95% CI, 30 to 90) reduced their dose ≥50% while 33% (2/6,
95% CI, 10 to 70) remained on high-dose PPI therapy.
Esophageal pH parameters at entry, six months after highdose PPI therapy and six months after TF in crossover patients are presented in Table 4.
Ancillary analyses

De novo dysphagia, bloating or excess flatulence was not
reported in crossover patients six months post TF. Statistically significant correlations between regurgitation,
atypical symptoms and pH parameters were not found
six months after high-dose PPI therapy and six months
after TF (Table 5). A moderate correlation between GERD-
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Table 1 Demographics and clinical characteristics of the study patients at screening
Characteristics

TF group (n = 39)

PPI group (n = 21)

p values

Male, n (%)

19 (49)

8 (38)

0.587

Age, years

54.5 (10.4)

50.4 (9.8)

0.151

Body mass index, kg/m2

28.3 (3.9)

29.1 (2.8)

0.422

GERD symptom duration, years

12.5 (11.3)

9.4 (5.7)

0.224

PPI therapy duration, years

9.3 (7.2)

8.1 (5.1)

0.686

3.7 (1.1)

4.1 (0.7)

0.122

Quality of life scores off PPIs
Reflux Disease Questionnaire (RDQ) score
Regurgitation (RDQ) score off PPIs

3.5 (1.2)

4.1 (0.9)

0.067

GERD-HRQL score

32.5 (9.6)

33.7 (8.5)

0.625

Heartburn score (GERD-HRQL)

22.2 (6.3)

23.2 (4.4)

0.519

Reflux Symptom Index (RSI) score

25.2 (9.3)

28.6 (7.4)

0.150

Total % time pH <4

10.2 (3.5)

10.6 (3.5)

0.665

Patients on single dose of PPI at entry, n (%)

27 (69)

16 (76)

0.765

GERD, gastroesophageal reflux disease; GERD-HRQL, gastroesophageal reflux disease health related quality of life; PPI, proton pump inhibitor; TF, transoral
fundoplication.

HRQL score and number of reflux episodes on high-dose
PPIs was found six months after high-dose PPI therapy.

TF group (12-month follow-up)
Primary endpoint

At 12-month follow-up off PPIs, global elimination of any
atypical symptoms and regurgitation was achieved in 77%
(30/39, 95% CI, 62 to 87) of patients; elimination of
troublesome regurgitation was achieved in 93% (28/30,
95% CI, 79 to 98). Elimination of all atypical symptoms
was experienced in 82% (32/39, 95% CI, 67 to 91) of
patients. There was no significant change in the various
QOL scores at different study intervals (Table 6).

Ancillary analyses

There were no reports of de novo dysphagia or bloating
at 12-month follow-up; one patient reported de novo excess flatulence (from score 0 at screening on PPIs to
score 3 off PPIs at 12-month follow-up).
In the TF group, correlation analyses between patient
reported subjective outcomes and pH outcomes off PPIs,
showed moderate statistically significant correlation between GERD-HRQL scores (typical symptoms) and objective outcomes at 12-month follow-up (Table 5). As
with the crossover group, statistically significant correlations between pH parameters, regurgitation and atypical
symptoms were not found.

Association analysis
Secondary endpoints

PPIs use, healing of reflux esophagitis and normalization
of esophageal acid exposure through the duration of the
study is shown in Figure 2. All esophageal pH parameters at 12-month follow-up were significantly reduced
compared to baseline (Table 4).

For the purpose of the association analysis, we increased our sample size by combining TF patients from
the original treatment group with crossover patients. Preoperative total number of long refluxes <12 (p <0.001),
DeMeester score <35 (p =0.011),% total time ≤10
(p =0.013) and absence of esophagitis (p =0.035) were

Table 2 Procedure data
Parameters

TF group (n = 39)

Crossover group (n = 21)

p values

Fasteners used, mean (range)

21 (16–30)

20 (10–30)

0.786

Valve length (cm), mean (range)

2.8 (2.5-4)

2.9 (2.5-4)

0.894

Valve circumference (degrees), mean (range)

290 (240–340)

300 (270–300)

0.647

Hiatal hernia reduced, n (%)

36 (100)

16 (100)

> 0.999

Hill grade I achieved (from Hill grade II), n (%)

31 (100)

18 (100)

> 0.999

Length of stay >24 hours, n (%)

2 (5)

1 (5)

> 0.999

Immediate post-operative endoscopy was used to assess hiatal hernia and Hill grade.
TF, transoral fundoplication.
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Table 3 Mean quality of life scores at screening (on PPIs), six months after high-dose proton-pump inhibitor (PPIs) and
six months after crossover to transoral fundoplication (TF) in patients initially randomized to the PPI group
Parameters

Screening
(on PPIs)

6-month on
6-month after p value (6-month p value (6-month p value (6-month
high-dose PPIs TF (off PPIs)
PPIs vs. screening) TF vs. screening PPIs vs. 6-month TF)

Reflux disease questionnaire (RDQ)

3.04 (0.99)

2.14 (1.20)

1.33 (1.76)

0.089

< 0.001

0.136

Heartburn (RDQ)

3.14 (1.31)

1.89 (1.37)

1.57 (1.96)

0.033

0.006

0.787

Dyspepsia (RDQ)

2.95 (1.21)

2.05 (1.31)

1.44 (1.92)

0.137

0.006

0.400

3.02 (1.09)

2.46 (1.28)

Regurgitation (RDQ)
Gastroesophageal reflux disease
health-related quality of life
(GERD-HRQL)
Heartburn (GERD-HRQL)
Reflux Symptom Index
Hoarseness
Throat clearing

0.98 (1.72)

0.398

< 0.001

0.003

26.43 (7.22) 18.86 (9.12)

10.05 (13.54)

0.053

< 0.001

0.020

16.90 (5.75) 11.67 (6.94)

7.48 (9.81)

0.078

< 0.001

0.189

22.62 (8.33) 19.62 (7.29)

8.76 (11.02)

0.151

< 0.001

< 0.001

2.19 (1.75)

0.95 (1.50)

0.979

0.034

0.020

2.29 (1.42)

2.90 (1.23)

2.90 (0.92)

1.23 (1.51)

> 0.999

< 0.001

< 0.001

Excess throat mucus or
postnasal drip

3.48 (1.14)

2.95 (0.84)

1.43 (1.56)

0.368

< 0.001

< 0.001

Difficulty swallowing foods,
liquids or pills

2.14 (1.28)

1.19 (1.18)

0.48 (0.96)

0.029

< 0.001

0.129

Coughing after eating or after
lying down

2.47 (1.57)

2.29 (1.35)

0.86 (1.53)

0.909

0.002

0.008

Breathing difficulties or chocking 1.57 (1.50)
episodes

1.19 (1.08)

0.38 (0.86)

0.550

0.005

0.075

Troublesome or annoying cough 2.14 (1.49)

2.33 (1.53)

0.90 (1.45)

0.910

0.025

0.008

Sensation or something sticking
or a lump in the throat (globus)

2.48 (1.44)

1.71 (1.10)

1.10 (1.76)

0.216

0.009

0.359

Heartburn, chest pain,
indigestion or stomach acid
coming up

3.24 (1.30)

2.76 (1.30)

1.43 (1.86)

0.566

< 0.001

0.016

Excess flatulence

2.62 (1.75)

2.24 (1.45)

0.70 (1.38)

0.702

< 0.001

0.006

Values represent means (standard deviations). PPI, proton pump inhibitor; TF, transoral fundoplication.

positively associated with normalization of EAE on univariate analyses. However, on a multivariate level, only preoperative total number of long refluxes <12 stayed
significantly associated with normalization of EAE (odds ratio 9.6, 95% CI 2.8 to 39.0, p <0.001). When this factor was
favorable, normalization of EAE in the TF group increased
from 45% to 65% (15/23, 95% CI, 45 to 81) at 12-month
follow-up. When this factor was unfavorable (≥12), pH
normalization was achieved in only 13% (2/15, 95% CI, 4 to
38) of TF patients. In crossover patients, when a number of
long refluxes were favorable, pH normalization was reached
in 56% (5/9, 95% CI, 27 to 81) of patients, six months following TF. When a number of long refluxes was ≥12, pH
normalization was achieved in 17% (2/12, 95% CI, 5 to 45)
of crossover patients.

Discussion
This report is the first to specifically investigate the effectiveness of TF in a controlled crossover design in patients
with partial control of regurgitation and extraesophageal
symptoms on high-dose PPI therapy. In the crossover
group of patients, six months of high-dose PPI therapy

provided measurable symptomatic improvement (Table 3),
while TF further improved control of a range of GERD
symptoms, particularly regurgitation and atypical symptoms. This is an important finding of this study. Patients
with typical GERD symptoms who demonstrate good response to PPI therapy are often considered to be the best
candidate for anti-reflux procedures [6]. Findings from
this study suggest that well selected patients (small hiatal
hernia, Hill grade I or II and esophagitis less than grade C)
with an incomplete response to dose escalation of PPIs
could also benefit from TF. It appears that in this study
TF was better than high-dose PPIs in the global elimination of regurgitation and all atypical symptoms (65% six
months after TF vs. 5% [10] six months of high-dose
PPIs). For this analysis, we elected to utilize a crossover
design rather than analyzing two parallel groups to eliminate any potential confounding factors that may influence
clinical outcomes.
The overall response of regurgitation to PPI therapy
has been estimated to be about 17% greater than placebo
and >20% less than that observed for heartburn [7]. In
the crossover group, 67% (6/9) of patients who reported
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Figure 2 Proton pump inhibitors use (A and B), healing of reflux esophagitis (C and D) and normalization of esophageal acid exposure
(E and F) in both treatment groups at different study intervals.
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Table 4 48-hour pH parameters through the phases of the study in patients initially randomized to the high-dose
proton-pump inhibitors (PPIs) group (A) and to the transoral fundoplication (TF) group (B)
A Parameters

Screening
(off PPIs)

6-month on
6-month after p value (6-month
high-dose PPIs TF (off PPIs)
PPIs vs. screening)

p value (6-month after p value (PPIs vs.TF)
TF vs. screening)

Number of refluxes

190.43 (89.36)

91.33 (68.01)

120.52 (64.25)

< 0.001

0.010

0.420

Number of long
12.52 (7.22)
refluxes (>5 minutes)

4.62 (5.07)

10.00 (6.02)

< 0.001

0.387

0.017

Duration of longest
reflux, minutes

26.48 (14.29)

23.76 (21.77)

24.86 (14.71)

0.867

0.950

0.977

Fraction time
pH <4, %

10.50 (3.51)

5.01 (4.55)

7.87 (4.20)

< 0.001

0.070

0.104

DeMeester score

35.79 (13.05)

19.29 (16.07)

28.60 (14.71)

0.002

0.258

0.108

B Parameters

Screening
(off PPIs)

6-month
(off PPIs)

12-month
(off PPIs)

p value (6-month vs.
screening)

p value (12-month vs.
screening)

p value (6-month vs.
12-month)

Number of refluxes

160.72 (76.71)

100.80 (83.58)

115.26 (61.28)

0.002

0.023

0.672

Number of long
12.62 (5.48)
refluxes (>5 minutes)

8.54 (7.68)

10.24 (7.89)

0.030

0.297

0.536

Duration of longest
reflux, minutes

31.36 (14.15)

23.41 (20.75)

23.82 (15.04)

0.010

0.128

0.994

Fraction time
pH <4, %

10.19 (3.55)

6.77 (5.41)

7.45 (4.86)

0.005

0.031

0.800

DeMeester score

35.28 (11.80)

23.64 (18.54)

25.32 (15.50)

0.004

0.016

0.883

Values represent means (standard deviation). PPI, proton pump inhibitor; TF, transoral fundoplication.

persistent troublesome regurgitation despite six months
of high-dose PPI therapy experienced complete elimination of regurgitation six months following TF. This
demonstrates a notable gain in a challenging patient
population and may well have important therapeutic implications. We believe that the ability of TF to eliminate
regurgitation is primarily due to the correction of anatomic defects at the gastro-esophageal junction [10].
Additionally, this report demonstrates that TF is capable of achieving a sustained control of regurgitation
and a range of atypical symptoms for at least 12 months
post-procedure (Table 6). In the TF group, the proportion of patients reporting elimination of troublesome regurgitation was stable between 6-month (97%) [10] and
12-month (93%) follow-up. We also noted that the proportion of patients reporting elimination of all atypical
symptoms increased from 62% at 6-month [10] to 82%
at 12-month, a finding in line with previous studies suggesting that atypical symptoms tend to resolve at a
slower pace than typical symptoms after anti-reflux surgery [16]. We suspect that the proportion of crossover
patients free of atypical symptoms 6-month post TF will
increase at 12-month follow-up as has been the case for
patients in the original TF group.
Complete discontinuation of acid-suppressive medications has been a common end point in many studies
evaluating surgical or endoscopic anti-reflux therapy.
Even occasional intake of PPIs to suppress GERD symptoms following anti-reflux procedures has been often
viewed as a treatment failure [17]. Of 7 patients (18%)

who continued taking any dose of PPIs 12 months following TF, elimination of troublesome regurgitation was
reported in 80% (4/5) of patients; elimination of troublesome atypical symptoms was achieved in 57% (4/7) of
patients. We believe that controlling troublesome symptoms and improving QOL with the use of PPIs after an
endoscopic anti-reflux procedure in patients who suffered from uncontrolled troublesome symptoms on highdose PPIs before intervention should not necessarily be
considered a treatment failure. This is the case in a sizable proportion of patients in our study. TF may therefore be viewed as a useful therapeutic adjunct to PPIs.
Pre-procedure patient counseling is mandatory in setting
appropriate expectations regarding the eventual need for
PPI use after TF.
A significant correlation between postoperative pH parameters, atypical symptoms and regurgitation were not
found in either treatment arm. A poor correlation between postoperative GERD symptoms and physiological
parameters has been reported previously after traditional
anti-reflux surgery [18,19]. Data on the correlation between symptomatic relief and pH parameters after highdose PPI therapy are sparse. In one prospective study,
50% of asymptomatic GERD patients on PPI therapy still
presented with abnormal pH study with 75% of studied
patients taking double-dose PPIs [20]. The most recent
study from Stanford University found that 54% of
asymptomatic GERD patients on PPI therapy still had
abnormal esophageal pH profiles [21]. This may suggest
that PPI therapy may be less efficacious in controlling
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Table 5 Correlation between objective (pH) and patient reported subjective outcomes in study patients PPI group on
PPIs (6 months following high-dose PPI therapy)
Parameters

Regurgitation

Regurgitation

1.00

RSI

0.70 (<0.001)

RSI

GERD-HRQL

DMS

% total time

RE

1.00

GERD-HRQL

0.59 (0.005)

0.71 (<0.001)

1.00

DMS

−0.20 (0.399)

0.05 (0.838)

0.38 (0.107)

1.00

% total time

−0.12 (0.619)

0.12 (0.598)

0.41 (0.063)

0.94 (<0.001)

1.00

RE

0.10 (0.667)

0.31 (0.167)

0.46 (0.035)

0.77 (<0.001)

0.84 (<0.001)

1.00

DMS

% total time

RE

Crossover patients off PPIs (6 months following transoral fundoplication)
Parameters

Regurgitation

Regurgitation

1.00

RSI

0.71 (<0.001)

RSI

GERD-HRQL

1.00

GERD-HRQL

0.81 (<0.001)

0.62 (0.003)

1.00

DMS

0.18 (0.428)

0.14 (0.556)

0.04 (0.866)

1.00

% total time

0.11 (0.637)

0.09 (0.705)

0.08 (0.746)

0.89 (<0.001)

1.00

RE

0.17 (0.461)

0.14 (0.546)

0.14 (0.543)

0.65 (0.001)

0.80 (<0.001)

1.00

GERD-HRQL

DMS

% total time

RE

TF group off PPIs (12 months following transoral fundoplication)
Parameters

Regurgitation

Regurgitation

1.00

RSI

RSI

0.66 (<0.001)

1.00

GERD-HRQL

0.42 (0.010)

0.73 (<0.001)

1.00

DMS

0.02 (0.885)

0.10 (0.550)

0.35 (0.036)

1.00

% total time

0.06 (0.724)

0.10 (0.552)

0.39 (0.018)

0.98 (<0.001)

1.00

RE

0.21 (0.216)

0.13 (0.424)

0.41 (0.013)

0.83 (<0.001)

0.84 (<0.001)

1.00

Values are Spearman’s Rho (p values).
DMS, DeMeester score; GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPI, proton pump inhibitor; RE, reflux episodes; RSI, Reflux
Symptom Index.
Regurgitation was assessed with Reflux Disease questionnaire. RSI was used to assess atypical symptoms. GERD-HRQL was used to assess typical symptoms.

abnormal esophageal acid exposure in certain patients
than previously thought. We speculate that the higher
prevalence of non-acid reflux or weekly acid reflux in
our population may explain the low rate of healing of reflux esophagitis in the PPI group [10]. The authors believe that the poor correlation between post-treatment
symptom control and pH data in both symptomatic and
asymptomatic patients warrants an effort to further define the role and significance of pH testing in this
setting.
High rates of symptomatic relief and healing of reflux
esophagitis after TF in this study were not matched by
equivalent rates of distal esophageal pH normalization.
Symptomatic relief may be more important than pH
normalization for some patients suffering from mild to
moderate symptoms and who are reluctant to undergo
more invasive surgical treatment options. We noted a
statistically insignificant decline in the proportion of patients who normalized distal EAE post TF (from 54% at
6- to 45% at 12-month). On the other hand, symptom
control improved and healing of reflux esophagitis

remained stable between two follow-up intervals. In
attempting to reconcile these apparently contradictory
findings, we speculate that the majority of patients in
this study may have suffered from non-acid reflux or experienced excessive proximal extent of reflux episodes
[10]. Additionally, there may be a potential for investigator bias toward the assessment of endoscopic findings.
The authors strongly suggest that future studies regarding treatments for GERD utilize pH impedance testing.
A recent report from the Maastricht University [22]
suggests that TF reduces the number of postprandial transient lower esophageal sphincter relaxations (TLESRs) and
the number of TLESRs associated with reflux. TF also is
shown to significantly reduce the distensibility of the
gastro-esophageal junction. It appears that the effect of TF
is selective for liquid-containing reflux episodes while the
number of gas reflux episodes remains unaffected, suggesting preservation of the ability of venting gas following
TF [22]. Although we were not able to confirm these important findings in our study since impedance testing was
not used, we believe that the findings from the Maastricht
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Table 6 Mean quality of life scores before transoral fundoplication (TF) and at 6- and 12- month follow-up in patients
initially randomized to the transoral fundoplication (TF) group
Parameters

Baseline (Before
TF on PPIs)

6-month
(off PPIs)

12-month
(off PPIs)

p value (6-month
vs. baseline)

p value (12-month p value (6-month
vs. baseline)
vs. 12-month)

Reflux disease questionnaire (RDQ)

2.91 (1.32)

0.35 (0.53)

0.50 (0.73)

< 0.001

< 0.001

0.772

Heartburn (RDQ)

2.99 (2.55)

0.45 (0.86)

0.63 (1.01)

< 0.001

< 0.001

0.776

Dyspepsia (RDQ)

2.81 (1.57)

0.42 (0.83)

0.53 (0.88)

< 0.001

< 0.001

0.917

Regurgitation (RDQ)
Gastroesophageal reflux disease
health-related quality of life
(GERD-HRQL)
Heartburn (GERD-HRQL)

2.94 (1.45)

0.19 (0.40)

0.33 (0.69)

< 0.001

< 0.001

0.791

26.25 (10.51)

5.23 (7.14)

5.41 (6.80)

< 0.001

< 0.001

0.995

17.69 (7.51)

3.74 (5.51)

3.76 (4.50)

< 0.001

< 0.001

> 0.999

Reflux Symptom Index

22.00 (9.63)

4.64 (5.53)

4.79 (6.67)

< 0.001

< 0.001

0.995

Hoarseness

1.76 (1.56)

0.18 (0.60)

0.33 (0.90)

< 0.001

< 0.001

0.810

Throat clearing

2.90 (1.37)

0.87 (1.28)

0.72 (1.10)

< 0.001

< 0.001

0.851

Excess throat mucus or
postnasal drip

2.77 (1.51)

0.87 (1.20)

0.79 (1.06)

< 0.001

< 0.001

0.961

Difficulty swallowing foods,
liquids or pills

1.92 (1.44)

0.33 (0.77)

0.46 (0.88)

< 0.001

< 0.001

0.858

Coughing after eating or
after lying down

2.46 (1.54)

0.44 (1.02)

0.44 (0.88)

< 0.001

< 0.001

> 0.999

Breathing difficulties or
choking episodes

1.85 (1.60)

0.13 (0.41)

0.33 (0.96)

< 0.001

< 0.001

0.690

Troublesome or annoying cough

2.21 (1.49)

0.49 (1.19)

0.54 (1.12)

< 0.001

< 0.001

0.983

Sensation or something sticking
or a lump in the throat (globus)

2.74 (1.41)

0.41 (0.94)

0.44 (0.75)

< 0.001

< 0.001

0.994

Heartburn, chest pain, indigestion 3.38 (1.39)
or stomach acid coming up

0.92 (1.22)

0.87 (1.26)

< 0.001

< 0.001

0.983

0.72 (1.19)

0.68 (1.1)

< 0.001

< 0.001

0.990

Excess flatulence

2.36 (1.65)

Values represent means (standard deviations).

University accurately present the mechanisms of the antireflux effect of TF. In our view, the consistent absence of
post-fundoplication symptoms associated with TF reported in previous studies [9], and confirmed in the
current study, represents one of the most attractive element of the TF procedure.
In this study, preoperative Hill grade (I or II) did not
affect post-operative clinical outcomes. Patients with more
severe anatomic defect (Hill grade III and IV) [23,24] and
more severe erosive disease [25] are less likely to respond
favorably to TF and were excluded from our study.
The TF procedure has demonstrated an acceptable safety
record. An exhaustive review of the published literature suggests a 3.2% incidence of serious adverse events associated
with the TF procedure [9]. In our study, the complete absence of any serious adverse events such as esophageal tears,
perforations or significant bleeding requiring transfusion is
likely due to the experience of the investigators who were all
past their learning curve for the TF (each performed more
than 20 TF cases before the study initiation) . This also suggests that proper technique and safe handling of the device
could help to further reduce incidence of complications.

There were some limitations to our study. First, this
was an open-label, pre-planned crossover, non-blinded
trial which may carry a certain unintended bias. Second,
although symptomatic control in the TF group improved
at 12-month compared to 6-month, a residual placebo
effect could still have impacted the reported results. Third,
the lack of pH impedance testing and systematic highresolution manometry data prevented us from clarifying
the presumed effects of TF on patients with non-acid and
proximal reflux, and on number of TLESRs. Finally, for
our association analysis, we combined the TF and the
crossover patient to increase the sample size. We believe
that these analyses should be repeated on a larger patient
population.
We focused our association analysis on normalization of
EAE since very few patients presented with recurring
GERD symptoms after TF. Our findings suggest that pH
normalization following TF could be improved by selecting appropriate patients with favorable preoperative objective characteristics. In this study, several factors were
positively associated with normalization of EAE on univariate level (preoperative total number of long refluxes <12,
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DeMeester score <35,% total time ≤10 and absence of
esophagitis; however, on a multivariate level, only preoperative total number of long refluxes <12 stayed significantly associated with normalization of EAE. Although
preoperative high resolution manometry was selectively
performed, we do not have any indications to believe that
this finding was due to poor preoperative esophageal motility. In fact, the increased number of long reflux events is
a significant driver of increased esophageal acid exposure
(personal communication Dr. Kahrilas). Furthermore, long
reflux events occur more common in the supine position
and are mainly a function of hiatal hernia size. We suspect
that relatively low number of long reflux events (<12) as a
predictive factor of normalization of EAE may suggest that
a large proportion of patients without hiatal hernia or very
small hiatal hernia may achieve normalization of EAE.
Plans are being made to perform a comprehensive analysis
of preoperative factors influencing post procedure
normalization of EAE on a large number of patients.
The patient population under study was characterized
by a mixed symptomatology with an incomplete response
to PPIs, which is representative of a clinical challenge
commonly encountered in the community setting. A previous report had also noted that the patient populations in
the majority of TF studies are skewed towards those with
the most severe GERD symptoms [9]. Our study achieved
notable results in controlling symptoms and healing of reflux esophagitis compared to high-dose PPIs. One may
speculate that even better results are possible in patients
with less severe, more homogeneous symptomatology.
Perhaps future studies could focus on the patient population with typical symptoms who completely respond to
PPI therapy and who have traditionally been considered
preferred candidates for anti-reflux surgery.

Conclusions
In conclusion, the results of this randomized study suggest that in patients with small hiatal hernias and an incomplete response to high-dose PPI therapy, TF can
further improve on the therapeutic effects achieved with
high-dose PPIs. It would appear that high-dose PPI therapy provides better control of the number of long
refluxes while other pH parameters are similarly improved with both therapies. Additionally, TF can safely
provide sustained control of regurgitation, atypical
symptoms and healing of reflux esophagitis for at least
12 months, without risking the development of postfundoplication side effects.
Additional file
Additional file 1: Transoral Fundoplication Procedure Video.
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